UCB propels Vimpat monotherapy along Keppra path, but can it beat Keppra?

UCB has reported positive Phase III data that shows that its anti-epileptic drug, lacosamide (Vimpat) performs better when used as monotherapy than when used an adjunct. This data, the company said, will be included as part of a supplemental new drug application (sNDA) submission to the US FDA in the second half of this year.

The data means that UCB may be able pursue a similarly deep incremental market penetration with Vimpat as with an...